Celonic AG, a global biologics development and manufacturing services provider, has completed the acquisition of Glycotope’s bio-manufacturing facility in Heidelberg, Germany.

The acquisition expands Celonic’s position in the high-growth CDMO market, with innovative technology platforms and expanded GMP manufacturing assets and capacity for late-stage and commercial supply.

Dr. Konstantin Matentzoglu, Celonic’s chief executive officer, said, “With on-boarding of almost two decades of invaluable experience in optimization of perfusion continuous manufacturing processes, Celonic is well positioned to offer our customers the flexibility and the advantages of perfusion and fed-batch manufacturing – from pilot to commercial scale. Also, adding Glycotope’s highly complementary GEX® human cell line platform to Celonic’s innovative CHOvolution integrated development platform gives our pharmaceutical and biotech customers the unique opportunity to select a tailored expression system, suitable for their bio-therapeutics development needs.”

Dr. Franzpeter Bracht, former chief operating officer of Glycotope and future COO of Celonic, added “The Heidelberg site fits well with the growth strategy of Celonic. Further investment plans to achieve a leading market position, not only ensures the continuation of more than 120 current jobs, but also provides a strong foundation for creation of future jobs at the site.”